Apimeds Pharmaceuticals US, Inc. (APUS)
NYSEAMERICAN: APUS · Real-Time Price · USD
1.410
+0.050 (3.68%)
May 29, 2026, 4:00 PM EDT - Market closed

APUS Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
18.4710.281.280.650.270.53
Research & Development
2.661.63-0.10.370.49
Total Operating Expenses
21.1411.911.280.750.641.02
Operating Income
-21.14-11.91-1.28-0.75-0.64-1.02
Interest Income
0.120.1100.01--
Interest Expense
-1-0.28-0.12-0.04-0.03-0.01
Other Non-Operating Income (Expense)
-21.986.09----
Total Non-Operating Income (Expense)
-19.845.91-0.11-0.03-0.03-0.01
Pretax Income
-40.97-6-1.39-0.78-0.67-1.03
Net Income
-40.97-6-1.39-0.78-0.67-1.03
Net Income to Common
-40.97-6-1.39-0.78-0.67-1.03
Shares Outstanding (Basic)
13118544
Shares Outstanding (Diluted)
13118544
Shares Change (YoY)
1275424.48%37.68%71.89%19.55%--
EPS (Basic)
-2.77-0.55-0.18-0.17-0.18-0.26
EPS (Diluted)
-2.77-0.55-0.18-0.17-0.18-0.26
Shares Outstanding
12.5812.587.97.93.853.85
Free Cash Flow
-11.31-8.98-0.73-0.63-0.45-0.82
Free Cash Flow Per Share
-0.89-0.83-0.09-0.14-0.12-0.21
EBITDA
-21.12-11.91-1.28-0.75-0.64-1.02
EBIT
-21.14-11.91-1.28-0.75-0.64-1.02
SEC Filings: 10-K · 10-Q